Follow MoonLake Immunotherapeutics AG. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
4 Stories in coverage 21 approved Programs 71 recruiting Registered trials 424B3 Nov 6 Latest SEC filing Nov 2 Latest story
Timeline 4 Pipeline 2 Trials 7
All4 Regulatory1 Trials and readouts2 Filings and people1
Pipeline by stage
Approved 1 Phase 3 1
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters Zug, V8 Incorporated Cayman Islands Industry Pharmaceutical Preparations Formerly Helix Acquisition Corp (to 2022) Also known as Helix Acquisition Corp, MLTX, MoonLake Immunotherapeutics How the company describes itself Clinical-stage biotech company developing SLK, a tri-specific Nanobody inhibiting IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa. source